![David M. Hilbert](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David M. Hilbert
Plus aucun poste en cours
Historique de carrière de David M. Hilbert
Anciens postes connus de David M. Hilbert
Sociétés | Poste | Début | Fin |
---|---|---|---|
Cellective Therapeutics, Inc.
![]() Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | Corporate Officer/Principal | 01/08/2004 | 14/11/2008 |
ARCELLX, INC. | Directeur/Membre du Conseil | 01/12/2014 | 22/01/2021 |
Directeur Général | 01/12/2014 | 22/01/2021 | |
Directeur Technique/Scientifique/R&D | 22/01/2021 | - | |
Fondateur | 01/12/2014 | - | |
President | 01/12/2014 | 22/01/2021 | |
National Cancer Institute
![]() National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - | - |
Human Genome Sciences, Inc.
![]() Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - | - |
Zyngenia, Inc.
![]() Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Directeur/Membre du Conseil | - | 06/07/2012 |
Directeur Technique/Scientifique/R&D | 06/11/2009 | - |
Formation de David M. Hilbert
Haverford College | Undergraduate Degree |
University of Pennsylvania | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 8 |
Opérationnelle
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Retail Trade | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ARCELLX, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Cellective Therapeutics, Inc.
![]() Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | Health Technology |
Zyngenia, Inc.
![]() Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Retail Trade |
Human Genome Sciences, Inc.
![]() Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
National Cancer Institute
![]() National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
- Bourse
- Insiders
- David M. Hilbert
- Expérience